Key result
Elevated natriuretic peptides predict cardiovascular mortality and heart failure in prediabetes and type 2 diabetes, though optimal cutoff points may require modification.
Why the study?
The discriminative potency of natriuretic peptides for cardiovascular death and heart failure clinical events beyond traditional risk factors in prediabetes and type 2 diabetes mellitus has not been established.
Does the measurement of circulating natriuretic peptides predict cardiovascular death and heart failure events in patients with prediabetes and type 2 diabetes mellitus?
Does the measurement of circulating natriuretic peptides predict cardiovascular death and heart failure events in patients with prediabetes and type 2 diabetes mellitus?
Answers are grounded in this paper and cite their sources.
Natriuretic peptide cutoff points may need modification for diagnosing and risk-stratifying heart failure in patients with type 2 diabetes, and their dynamics during treatment with novel antidiabetic agents require further study.
Prediabetes and diabetes mellitus (DM) are established risk factors for newly occurred heart failure (HF) with reduced and preserved ejection fraction. Natriuretic peptides (NPs) were found to be useful tool for CV risk stratification among patients with prediabetes and type 2 DM (T2DM) regardless of HF phenotype. Previous clinical studies have shown that elevated levels of NPs predicted all-cause mortality and CV mortality, risk of HF occurrence and progression, as well as a risk readmission due to HF. The discriminative potency of NPs for CV death and HF-related clinical events in prediabetes and T2DM populations has not been demonstrated beyond traditional CV risk factors. The aim of the review is to accumulate knowledge regarding predictive value of circulating NPs depending on presentation of prediabetes and established T2DM. It has been found that HFrEF or HFpEF in T2DM patients may require modification of NP cutoff points to primary diagnose HF and determine HF-related risks. There are several controversies between clinical outcomes and dynamic of circulating levels of NPs in diabetics treated with glucagon-like peptide-1 agonists and sodium-glucose cotransporter-2 inhibitors that require to be elucidated in large clinical studies in the future.
No takes yet. Share an insight, caveat, or question.
Alexander Е. Berezin (2020) conducted a review in Prediabetes and type 2 diabetes mellitus. Natriuretic peptides was evaluated. Elevated natriuretic peptides predict cardiovascular mortality and heart failure in prediabetes and type 2 diabetes, though optimal cutoff points may require modification.
Synapse has enriched 10 related papers. Consider them for comparative context: